The Philippines on Friday suspended the programme, after more than 733,000 people had been immunised, in response to a statement from Sanofi that its vaccine could cause "more cases of severe disease" for people who had not previously had the mosquito-borne ailment.
After news outlets and some politicians in the Philippines expressed concern about the welfare of those immunised, the French pharaceutical giant held a press conference in Manila to state the potential cases of "severe dengue" would not be fatal.
Sta. Ana said Sanofi's definition of "severe dengue" merely referred to symptoms including two days of fever, a lower platelet count and bruising.
Philippine presidential spokesman Harry Roque also sought to allay fears, stating there was "no danger" with the Dengvaxia vaccine.
Also Read
"The worst that can happen is for those who have not had dengue before -- which is one out of 10 (Filipinos) -- they may get infected with dengue but falling under our previous classification of 'mild', having fever and bruises," Roque said.
The previous administration of president Benigno Aquino launched the vaccination programme last year, making the Philippines the first nation to use Dengvaxia on a mass scale.
Although the Philippine programme has been suspended, Dengvaxia remains available on an individual basis in consultation with doctors, the health department said.
Disclaimer: No Business Standard Journalist was involved in creation of this content